Clinical Trials Logo

Lichen Planus clinical trials

View clinical trials related to Lichen Planus.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05170308 Withdrawn - Clinical trials for Lichen Planus Pigmentosus

Fractional CO2 Laser for the Treatment of Lichen Planus Pigmentosus

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

This study will assess the safety and efficacy of fractional carbon dioxide (CO2) laser treatment for Lichen Planus Pigmentosus (LPP). LPP is a chronic pigmentary disorder typically involving the forehead, lateral cheeks, and occasionally other sun-exposed areas such as the forearms. Clinically, LPP appears as a reticulated brown to black macules and patches. Previously studied effective treatments of LPP include topical tacrolimus and corticosteroids. LPP is often recalcitrant to therapy, with chronic maintenance treatment needed to prevent repigmentation. There are few reports of laser modalities being used to treat LPP, with Nd:YAG being the only published laser modality to be attempted. Although topical therapies are relatively safe, there is a lack of satisfactory treatment options for this patient population. Fractional CO2 laser has been widely used for photoaging due to its effectiveness and high safety profile. Clinically evident improvement can be appreciated even after only one session of treatment. Ablative fractional laser resurfacing is both safe and effective for the treatment of the vascular, pigmentary and textural components of skin disorders. No data exist regarding the use of fractional CO2 laser for management of LPP. This study hopes to fulfill this purpose. The study subjects' body will be divided into two equal halves along sagittal midline section with one side receiving treatment with fractional CO2 laser (experimental) and the other left untreated (control)

NCT ID: NCT03836885 Withdrawn - Oral Lichen Planus Clinical Trials

Apremilast - Oral Lichen Planus Trial

APOLP
Start date: November 21, 2019
Phase: Phase 2
Study type: Interventional

Apremilast for the management of oral lichen planus.